The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective

被引：30
|
作者：
Hayward, Carl [1 ]
Banner, Nicholas R. [2 ]
Morley-Smith, Andrew [1 ]
Lyon, Alexander R. [1 ]
Harding, Sian E. [3 ]
机构：
[1] Royal Brompton Hosp, Cardiovasc Biomed Res Unit, London SW3 6NP, England
[2] Royal Brompton & Harefield NHS Trust, Harefield Hosp, Harefield UB9 6JH, Middx, England
[3] Univ London Imperial Coll Sci Technol & Med, London SW3 6NP, England
来源：
HUMAN GENE THERAPY | 2015年 / 26卷 / 05期
关键词：
SARCOPLASMIC-RETICULUM CA2+-ATPASE; SMOOTH-MUSCLE-CELLS; CALCIUM UP-REGULATION; NEUTRALIZING ANTIBODIES; DILATED CARDIOMYOPATHY; CARDIAC-FUNCTION; VENTRICULAR-ARRHYTHMIAS; MYOCARDIAL-INFARCTION; FAILING HUMAN; RAT MYOCYTES;
D O I：
10.1089/hum.2015.018
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Gene therapy has been applied to cardiovascular disease for over 20 years but it is the application to heart failure that has generated recent interest in clinical trials. There is laboratory and early clinical evidence that delivery of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy is beneficial for heart failure and this therapy could become the first positive inotrope with anti-arrhythmic properties. In this review we will discuss the rationale for SERCA2a gene therapy as a viable strategy in heart failure, review the published data, and discuss the ongoing clinical trials, before concluding with comments on the future challenges and potential for this therapy.
引用
收藏
页码：293 / 304
页数：12
相关论文
共 50 条
  • [1] Current Landscape of Heart Failure Gene Therapy
    Kieserman, Jake M.
    Myers, Valerie D.
    Dubey, Praveen
    Cheung, Joseph Y.
    Feldman, Arthur M.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (10):
  • [2] Gene Therapy in Heart Failure-SERCA2a as a Therapeutic Target -
    Hayward, Carl
    Patel, Hitesh
    Lyon, Alexander
    CIRCULATION JOURNAL, 2014, 78 (11) : 2577 - 2587
  • [3] Molecular targets in heart failure gene therapy: current controversies and translational perspectives
    Kairouz, Victor
    Lipskaia, Larissa
    Hajjar, Roger J.
    Chemaly, Elie R.
    EVOLVING CHALLENGES IN PROMOTING CARDIOVASCULAR HEALTH, 2012, 1254 : 42 - 50
  • [4] SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope
    Sikkel, Markus B.
    Hayward, Carl
    MacLeod, Kenneth T.
    Harding, Sian E.
    Lyon, Alexander R.
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (01) : 38 - 54
  • [5] Heart Failure Gene Therapy The Path to Clinical Practice
    Pleger, Sven T.
    Brinks, Henriette
    Ritterhoff, Julia
    Raake, Philip
    Koch, Walter J.
    Katus, Hugo A.
    Most, Patrick
    CIRCULATION RESEARCH, 2013, 113 (06) : 792 - 809
  • [6] SERCA2a Gene Therapy for the Prevention of Sudden Cardiac Death A Future Theranostic for Heart Failure?
    Shah, Sanjiv J.
    Wasserstrom, J. Andrew
    CIRCULATION, 2012, 126 (17) : 2047 - 2050
  • [7] Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy
    Samuel, T. Jake
    Rosenberry, Ryan P.
    Lee, Seungyong
    Pan, Zui
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (04)
  • [8] Gene Therapy for Heart Failure
    Tilemann, Lisa
    Ishikawa, Kiyotake
    Weber, Thomas
    Hajjar, Roger J.
    CIRCULATION RESEARCH, 2012, 110 (05) : 777 - 793
  • [9] The Future of Pharmacological Therapy for Heart Failure
    Sata, Yusuke
    Krum, Henry
    CIRCULATION JOURNAL, 2010, 74 (05) : 809 - 817
  • [10] Myocardial regeneration therapy in heart failure: Current status and future therapeutic implications in clinical practice
    Banovic, Marko
    Pusnik-Vrckovnik, Maja
    Nakou, Eleni
    Vardas, Panos
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 260 : 124 - 130
12345